Core Insights - AbbVie reported quarterly earnings of $2.71 per share, exceeding the Zacks Consensus Estimate of $2.66 per share, and showing an increase from $2.16 per share a year ago, resulting in an earnings surprise of +2.02% [1] - The company achieved revenues of $16.62 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.58% and increasing from $15.1 billion year-over-year [2] Earnings Performance - AbbVie has consistently surpassed consensus EPS estimates over the last four quarters, with the latest earnings surprise being +5.08% compared to the previous quarter's expectation of $1.77 per share [1][2] - The current consensus EPS estimate for the upcoming quarter is $3.12, with projected revenues of $15.2 billion, and for the current fiscal year, the estimate is $14.32 on revenues of $67.28 billion [7] Stock Performance and Outlook - AbbVie shares have underperformed the market, losing about 1.2% since the beginning of the year, while the S&P 500 has gained 1.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Large Cap Pharmaceuticals industry, to which AbbVie belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Eli Lilly (LLY) came out with quarterly earnings of $7.54 per share, beating the Zacks Consensus Estimate of $6.99 per share. This compares to earnings of $5.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +7.88%. A quarter ago, it was expected that this drugmaker would post earnings of $6.02 per share when it actually produced earnings of $7.02, delivering a surprise of +16.61%.Over the last four quarters, the company has ...

分组1 - Pfizer reported quarterly earnings of $0.66 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and showing an increase from $0.63 per share a year ago, resulting in an earnings surprise of +16.81% [1] - The company achieved revenues of $17.56 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.26%, although this represents a decline from year-ago revenues of $17.76 billion [2] - Pfizer has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 7.1% since the beginning of the year, outperforming the S&P 500, which has gained 1.9% [3] - The future performance of Pfizer's stock will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.75 on revenues of $13.9 billion, and for the current fiscal year, it is $2.97 on revenues of $60.81 billion [7] 分组3 - The Large Cap Pharmaceuticals industry, to which Pfizer belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The Zacks Rank for Pfizer is currently 5 (Strong Sell), suggesting that the stock is expected to underperform the market in the near future [6]

Merck (MRK) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +0.62%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $2.36 per share when it actually produced earnings of $2.58, delivering a surprise of +9.32%.Over the last four quarters, the comp ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Eli Lilly (LLY) , which belongs to the Zacks Large Cap Pharmaceuticals industry.This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 14.54%.For the last reported quarter, Lilly came out with earnings of $7.02 per share versus the Zacks Conse ...

Core Viewpoint - AbbVie (ABBV) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings expected to be $3.02 per share, reflecting a +39.8% change, and revenues projected at $16.38 billion, up 8.5% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 4, and the stock may rise if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 0.32% higher in the last 30 days, indicating a slight positive adjustment from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that AbbVie has a negative Earnings ESP of -12.44%, suggesting analysts have become bearish on the company's earnings prospects [12]. - Despite the negative Earnings ESP, AbbVie holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - AbbVie has a history of beating consensus EPS estimates, having done so in the last four quarters, with a recent surprise of +5.08% when it reported earnings of $1.86 per share against an expectation of $1.77 [13][14]. Industry Context - In the broader pharmaceutical industry, Merck (MRK) is also expected to report earnings of $2.04 per share for the same quarter, reflecting a year-over-year change of +18.6%, with revenues projected at $16.19 billion, up 3.6% [18]. - Merck's consensus EPS estimate has been revised down by 85.2% over the last 30 days, and it currently has an Earnings ESP of +0.33% but holds a Zacks Rank of 4, complicating predictions for an earnings beat [19][20].

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.05%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.77 per share when it actually produced earnings of $2.8, delivering a surprise of +1.08%.Ove ...

Company Overview - Arcellx, Inc. (ACLX) is part of the Medical group, which consists of 932 companies and currently ranks 8 within the Zacks Sector Rank [2] - The company belongs to the Medical - Biomedical and Genetics industry, which includes 453 companies and is ranked 93 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, Arcellx, Inc. has returned approximately 10.7%, outperforming the average gain of 6% for Medical stocks [4] - The Zacks Consensus Estimate for ACLX's full-year earnings has increased by 1.2% over the past quarter, indicating improved analyst sentiment [4] Comparison with Peers - Bayer Aktiengesellschaft (BAYRY), another Medical stock, has outperformed the sector with a year-to-date return of 15.6% and a Zacks Rank of 1 (Strong Buy) [5] - The Large Cap Pharmaceuticals industry, which includes Bayer, has gained 19.8% since the beginning of the year, while Arcellx, Inc. is slightly underperforming its industry group [6][7]

Wall Street expects a year-over-year increase in earnings on higher revenues when Johnson & Johnson (JNJ) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Janua ...